key: cord-0871503-5uj42nj0
authors: Bansal, Naveen; Raturi, Manish; Bansal, Yashik
title: COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors
date: 2021-05-07
journal: Transfus Clin Biol
DOI: 10.1016/j.tracli.2021.05.002
sha: c21d827ff6ad06e4ea18bd20f9857cc28dd5c041
doc_id: 871503
cord_uid: 5uj42nj0

Clinical management protocols for COVID-19 are evolving rapidly as more information about the epidemiology and pathophysiological changes in COVID-19 becomes available. However, no definite treatment of COVID-19 pandemic has been found till date. The COVID-19 convalescent plasma (CCP) therapy has emerged as an important investigational therapy in the management of COVID-19 patients. Additionally, the regulatory agencies, in particular, the Indian blood transfusion council must release some interim recommendations for the blood centres on the CCP blood donor eligibility criteria after COVID-19 vaccination. More clinical trials are needed to know the efficacy of the CCP harvested from COVID-19 recovered individuals who have been vaccinated against the COVID-19 recovered individuals who are not vaccinated to understand the vaccine impact on the IgG titre of anti-SARS-Cov-2 antibodies.

of CCP containing high titre IgG anti-SARS-CoV-2 antibodies for the therapy to be effective [12] .

Further, we believe that there might be a lot of paranoia, uncertainty and false assumptions in the minds of donors about whole blood donation [WBD] as well as CCP donation amid this pandemic [13] . The efforts to develop an effective vaccine started as soon as February 2020. In fact, as of 20th April 2021, a total of six vaccines have been given emergency use authorization [EUA] by the World Health Organization recognized stringent regulatory authorities. Also, mass immunization programs against SARS-CoV-2 are currently going on in various countries throughout the globe. Therefore, there are now two types of seroconverted individuals:

Those as a result of natural infection with the SARS-CoV-2 virus and;

(ii) Those as a result of vaccination against SARS-CoV-2.

Additionally, with the overtly visible role of a transfusion medicine specialist [TMS] in the community these days [14] , the scientific community is bound to ask them the following three queries: and no deferral period for receiving an inactivated or killed vaccine [16] . While, few regulatory agencies have issued guidelines for donor deferral towards WBD following COVID-19 vaccination [17] , others have largely remained silent on defining an appropriate deferral period for CCP donation in such vaccinated individuals. Furthermore, it has also been seen that previously infected individuals are producing very high titre SARS-CoV-2 specific neutralizing antibodies following vaccination [18] .

Therefore, the CCP obtained from these individuals may be more effective in the COVID-19 treatment than the CCP obtained from non-vaccinated COVID-19 recovered patients.

Query 3: CCP donor eligibility for the COVID-19 recovered individuals who themselves received CCP therapy during their hospital stay?

Discussion: All the donors who wish to make either a WBD or CCP donation must meet the allogeneic blood donor criteria as well as the deferral requirements, including the three-month deferral from the date of CCP administration or the transfusion of any other blood component [16] .

To conclude, the regulatory agencies, in particular, the Indian blood transfusion council must release some interim recommendations on the CCP donor eligibility in the aforementioned situations. Additional clinical trials are needed to know the efficacy of the CCP harvested from COVID-19 recovered individuals who have been vaccinated against the COVID-19 recovered individuals who are not vaccinated.

The authors declare that there are no conflicts of interest.

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies

A look-back at convalescent plasma to treat COVID-19

Current Perspectives of convalescent plasma therapy in COVID-19

Convalescent Plasma Therapy for COVID-19: State of the Art

Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Can I donate blood" self-assessment tool amid the COVID-19 outbreak

Recognizing the role of transfusion medicine specialist in the modern era

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Updated information on donation of CPP, blood components and HCT/ Ps during the COVID-19 pandemic

COVID-19 vaccination in the Indian blood donors: Adjudging the impact on the deferral period

Antibody Response in Persons with Past Natural Infection